Table 1 Clinical course
Day of TKI treatment | Clinical event | qPCR BCR/ABL, Blood (IS units) | qPCR BCR/ABL, Marrow (IS units) | T lymphoblasts, Marrow |
|---|---|---|---|---|
−1 | CML diagnosis confirmed | 44 % | 9 % | |
1 | Started imatinib 500 mg daily | |||
22 | 58 % | |||
25 | 65 % | 1 % | ||
29 | 69 % | |||
34 | 50 % | |||
41 | 67 % | |||
49 | Started dasatinib 100 mg daily | 56 % | ||
54 | 52 % | 52 % | 0.02 % | |
64 | 28 % | |||
68 | 22 % | |||
92 | 4.3 % |